Company intelligence / Profile preview
Cubed Biotech
Montréal, Quebec, Canadacubed3biotech.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Cubed Biotech is developing psychedelic-based medicines, including psilocybin and psilocin from mushrooms, mescaline from cacti, and DMT/MAO-inhibitors from Ayahuasca. Their lead programs are in preclinical development with plans for clinical trials targeting mental health and addiction. No clinical results have been reported yet.
- Therapeutic areas
- Psychiatry
- Modalities
- Small moleculeNatural productPsychedelic compoundStacked multiple active pharmaceutical ingredient (API) formula
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Cubed Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cubed Biotech.